Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Yerushalmi, Rinat, Mina, Lida A., Martin, Miguel, Roché, Henri, Im, Young-Hyuck, Quek, Ruben G.W., Markova, Denka, Tudor, Iulia C., Hannah, Alison L., Eiermann, Wolfgang, Blum, Joanne L.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1802905

Cited by (1,000)

Items 701–800 of 1,000

The role of Real-World Data and evidence in oncology medicines approved in EU in 2018–2019
Sini Marika Eskola, Hubert G. M. Leufkens, Andrew Bate, Marie L. De Bruin, Helga Gardarsdóttir · 2023 · Journal of Cancer Policy
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
Stefania Morganti, Brittany Bychkovsky, Philip Daniel Poorvu, Ana Christina Garrido-Castro, Anna Catherine Weiss, Caroline Cole Block, Ann H. Partridge, Giuseppe Curigliano, Nadine Tung, NU Lin et al. · 2023 · The Oncologist
A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm
Arya Mariam Roy, Vasanthan Muthusamy Kumarasamy, Ajay Dhakal, Ruth M O'Regan, Shipra Gandhi · 2023 · Cancer
Advanced Triple-Negative Breast Cancer
Grisma Patel, Alison Prince, Mark Harries · 2023 · Seminars in Oncology Nursing
Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived Xenografts
James H. Laird, Benjamin H. Lok, Brandon D. Carney, Susanne Kossatz, Elisa de Stanchina, Thomas Reiner, John Thomas Poirier, Charles M. Rudin · 2019 · Journal of Thoracic Oncology
Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
David S. Lakomy, Diana L. Urbauer, Shannon Neville Westin, Lilie L. Lin · 2019 · Clinical and Translational Radiation Oncology
Olaparib for Advanced Breast Cancer
Gaia Griguolo, Maria Vittoria Dieci, Federica Miglietta, Valentina Guarneri, PierFranco Conte · 2020 · Future Oncology
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101
Jelinek, Michael J., Foster, Nathan R., Zoroufy, Alex J., Schwartz, Gary K., Munster, Pamela N., Seiwert, Tanguy Y., de Souza, Jonas A., Vokes, Everett E. · 2021 · Oral Oncology
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Евгений Наумович Имянитов · 2021 · Hereditary Cancer in Clinical Practice
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Mehrnoosh Pauls, Stephen Chia, Nathalie LeVasseur · 2022 · Current Oncology
The Landscape of PARP Inhibitors in Solid Cancers
Marta Muzzana, Massimo Broggini, Giovanna L.M. Damia · 2025 · OncoTargets and Therapy
Novel strategies in breast cancer management: From treatment to long-term remission
Sina Habibi, Shabbou Bahramian, Saeedeh Zare Jalise, Sara Mehri, Shima Ababzadeh, Maria Kavianpour · 2025 · Critical Reviews in Oncology/Hematology
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
Yen‐Shen Lu, Winnie Yeo, Yoon Sim Yap, Yeon Hee Park, Kenji Tamura, Huiping Li, Rebecca Cheng · 2021 · Targeted Oncology
BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review
Liye Wang, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Shusen Wang, Fei Xu · 2021 · Oncology Research and Treatment
Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low‐to‐middle income Asian country
Yong‐Quan Lee, Sook‐Yee Yoon, Tiara Hassan, Heamanthaa Padmanabhan, Cheng Har Yip, Keng Wee Teik, Meow‐Keong Thong, Muhammad Azrif Ahmad Annuar, Nur Aishah Mohd Taib, Soo‐Hwang Teo · 2022 · Journal of Genetic Counseling
Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors
Mohammad Mahmoud Al-Sanea, Garri Chilingaryan, Narek Abelyan, Michael Mamikonyan, Hayk A. Gasparyan, Sargis A. Hovhannisyan, Abdelrahman Hamdi, Ahmed R. Ali, Samy Selim, Ahmed A. B. Mohamed · 2022 · PLoS ONE
Emerging Targeted Therapies for Early Breast Cancer
Ilana Miriam Schlam, Paolo Tarantino, Stefania Morganti, Filipa C. Lynce, Dario Trapani, Erica L. Mayer, Ana Christina Garrido-Castro, Ada Waks, Sara M. Tolaney · 2022 · Drugs
ERCC6L facilitates the onset of mammary neoplasia and promotes the high malignance of breast cancer by accelerating the cell cycle
Yang Hong, Xiangjin Zhen, Yihui Yang, Yizhi Zhang, Sen Zhang, Hao Yue, Guanhua Du, Hongquan Wang, Bailin Zhang, Li Wan et al. · 2023 · Journal of Experimental & Clinical Cancer Research
DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review
Zoe Phan, Caroline Elizabeth Ford, Catherine Elizabeth Caldon · 2023 · Pharmacological Research
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma
Lorenza P. Ferretti, Flurina Böhi, Deena M. Leslie Pedrioli, Phil Fang Cheng, Elena Ferrari, Petra Baumgaertner, Abdiel Alvarado-Diaz, Federica Sella, Alessandra Cereghetti, Patrick Turko et al. · 2023 · Cancer Research
Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
Peng Yuan, Nan Ma, Binghe Xu · 2024 · Medicinal Research Reviews
Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings
AC Houts, Tope Olufade, Rahul A. Shenolikar, Mark Stephen Walker, Lee Steven Schwartzberg · 2019 · Cancer Treatment and Research Communications
Prevalence of germline variants in inflammatory breast cancer
Huma Q. Rana, Rosalba E. Sacca, Christine M. Drogan, Stephanie Gutierrez, Emily Schlosnagle, Meredith M. Regan, Virginia Speare, Holly LaDuca, Jill S. Dolinsky, Judy Ellen Garber et al. · 2019 · Cancer
Gastrointestinal events with PARP inhibitors in cancer patients: A meta‐analysis of phase II/III randomized controlled trials
Wenxia Sun, Jing Li, Zhifeng Zhang, Xueyan Su · 2020 · Journal of Clinical Pharmacy and Therapeutics
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Won‐Ji Ryu, Joohyuk Sohn · 2021 · Pharmaceuticals
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment
Sofia Genta, Federica Martorana, Anastasios Stathis, Ilaria Colombo · 2021 · Critical Reviews in Oncology/Hematology
Current State of Cell Therapies for Breast Cancer
Namrata Gautam, Kelly M. Elleson, Ganesan Ramamoorthi, Brian J. Czerniecki · 2022 · The Cancer Journal
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
Alessandro Adriano Viansone, Benedetta Pellegrino, Claudia Omarini, Mirco Pistelli, Daniela Boggiani, Angelica Sikokis, Vera Uliana, Daniele Zanoni, Chiara Tommasi, Beatrice Bortesi et al. · 2022 · The Breast
The Present and Future of Clinical Management in Metastatic Breast Cancer
Pauline Lin, George Laliotis · 2022 · Journal of Clinical Medicine
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
Sara Alsterlind Hurvitz, R.G.W. Quek, Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva‐Maria Grischke, Lida A. Mina, Judith Balmañà et al. · 2018 · European Journal of Cancer
Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers
Shani Koshrovski‐Michael, Daniel Rodriguez Ajamil, Pradip Dey, Ron Kleiner, Shahar Tevet, Yana Epshtein, Marina Green Buzhor, Rami Khoury, Sabina Pozzi, Gal Shenbach‐Koltin et al. · 2024 · Science Advances
Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies
Andreas Schneeweiß, Andreas Daniel Hartkopf, Volkmar Müller, Achim Wöckel, Michael Patrick Lux, Wolfgang Janni, Johannes Ettl, Erik Belleville, Jens Huober, Marc Thill et al. · 2020 · Geburtshilfe und Frauenheilkunde
DEVELOPMENT OF 1-(4-SUBSTITUTEDPIPERAZIN-1-YL)-2-(2,4-METHOXYBENZYLTHIO) PYRIMIDIN-4-YLOXYETHANONES THAT TARGET POLY ADP-RIBOSE POLYMERASE IN HUMAN BREAST CANCER CELLS.
Suresha N. Deveshegowda, Prashant K. Metri, Rashmi Shivakumar, Ji-Rui Yang, Shobith Rangappa, Ananda Swamynayaka, Muthu Kumaraswamy Shanmugam, Omantheswara Nagaraja, Madegowda Mahendra, Priya Babu Shubha et al. · 2022 · Molecules
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes
Elisabetta Todisco, Federica Gigli, Chiara Ronchini, Viviana Amato, Simona Sammassimo, Rocco Pastano, Gabriella Parma, M. Lapresa, Francesco Bertolini, Chiara Antonia Corsini et al. · 2022 · International Journal of Cancer
Breast Cancer Genomics: Primary and Most Common Metastases
Caroline Bennett, Caleb Carroll, Cooper Wright, Barbara Awad, Jeong Mi Park, Meagan B. Farmer, Elizabeth (Bryce) Brown, Alexis Heatherly, Stefanie A Woodard · 2022 · Cancers
Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
Sarah Edaily, Hikmat Abdel‐Razeq · 2022 · OncoTargets and Therapy
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
Gaurav Kumar Pandey, Nick Landman, Hannah K. Neikes, Danielle Hulsman, Cor Lieftink, Roderick L. Beijersbergen, Krishna Kalyan Kolluri, Sam M. Janes, Michiel Vermeulen, Jitendra Badhai et al. · 2023 · Cell Reports Medicine
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Sharvina Ziyeh, Lauren Wong, Reva Kakkar Basho · 2023 · Current Oncology Reports
Metastatic Triple-Negative Breast Cancer
Xiaojie Zhang, Kay T. Yeung · 2023 · Current Breast Cancer Reports
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial
Michael Leonard Friedlander, Linda Mileshkin, Janine Margaret Lombard, Sophia Frentzas, Bo Gao, Michelle K. Wilson, Tarek M. Meniawy, Sally E. Baron-Hay, Karen P. Briscoe, Nicole McCarthy et al. · 2023 · British Journal of Cancer
Multi-scale characterisation of homologous recombination deficiency in breast cancer
Daniel H. Jacobson, Pan Shi, Jasmin Fisher, Maria Secrier · 2023 · Genome Medicine
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024
Tjoung‐Won Park‐Simon, Volkmar Müller, Ute‐Susann Albert, Malgorzata Joanna Banys-Paluchowski, Ingo Bauerfeind, Jens‐Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Caroline Ditsch, Eva Maria Fallenberg et al. · 2024 · Breast Care
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
Gordon Richard Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin Paul Dowling, Maen Monketh Alrawashdeh, Arnold D. K. Hill, Damir Varešlija, Leonie S. Young · 2024 · Current Oncology Reports
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD
Anna J. Dellomo, Maria R. Baer, Feyruz Virgilia Rassool · 2019 · Cancer Letters
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
Jennifer S. Winn, Zachary Hasse, Michael J. Slifker, Jianming Pei, Sebastian M. Arisi-Fernandez, Jacqueline N. Talarchek, Elias I. Obeid, Donald A. Baldwin, Yulan Gong, Eric A. Ross et al. · 2020 · International Journal of Molecular Sciences
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu · 2020 · Frontiers of Medicine
Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer
Matthew J. Wongchenko, Sung‐Bae Kim, Cristina Saura, Mafalda Oliveira, Doron Lipson, Mark Kennedy, Mandy Greene, Virginia Breese, Aruna Mani, Na Xu et al. · 2020 · JCO Precision Oncology
Molecular Features and Clinical Management of Hereditary Gynecological Cancers
Arisa Ueki, Akira Hirasawa · 2020 · International Journal of Molecular Sciences
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Francesco Schettini, Silvia Paola Corona, Fabiola Giudici, Carla Strina, Marianna Sirico, Ottavia Bernocchi, Manuela Milani, Nicoletta Ziglioli, Sergio Aguggini, Carlo Azzini et al. · 2021 · Frontiers in Oncology
The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data
Panagiota Gianni, Evangelia Matenoglou, Georgios Geropoulos, Nirav Agrawal, Harsha Adnani, Stefanos Zafeiropoulos, Santiago J. Miyara, Sara Guevara, James M. Mumford, Ernesto P. Molmenti et al. · 2021 · Clinical Breast Cancer
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology
Shreya M. Shah, Elena V. Demidova, Randy W. Lesh, Michael J. Hall, Mary Beryl Daly, Joshua E. Meyer, Martin Joseph Edelman, Sanjeevani Arora · 2022 · Cancer Treatment Reviews
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi, Ben O’Leary, Bradley Stephen Wubbenhorst, Emanuela Ferraro, Enrico Moiso, Minna Lee, Julia Ah-Reum An, Mark T.A. Donoghue et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1 / 2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
Ayoub, Jean-Pierre, Wildiers, Hans, Friedlander, Michael, Arun, Banu K., Han, Hyo S., Puhalla, Shannon, Shparyk, Yaroslav, Jakobsen, Erik H., Wu, Meijing, Bach, Bruce A. et al. · 2021 · Therapeutic Advances in Medical Oncology
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
Eva Blondeaux, L. Boni, Giovanna Chilà, Arianna Dri, Roberta Caputo, Francesca Benedetta Poggio, Alessandra Fabi, Grazia Arpino, Federico Pravisano, Elena Geuna et al. · 2025 · ESMO Open
Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
Ying-Wen Wang, Isaac Allen, Ionut-Gabriel Funingana, Marc D. Tischkowitz, Walburga Yvonne Joko-Fru · 2025 · BJC Reports
Health Disparities in Germline Genetic Testing for Cancer Susceptibility
Divya Ahuja Parikh, James Charles Dickerson, Allison W. Kurian · 2020 · Current Breast Cancer Reports
Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
Martina Dameri, Lorenzo Ferrando, Gabriella Cirmena, Claudio Vernieri, Giancarlo Pruneri, Alberto Ballestrero, Gabriele M. Zoppoli · 2021 · International Journal of Molecular Sciences
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics
Emma G. Sturgill, Amanda Misch, Rebecca Lachs, Carissa C. Jones, Dan Schlauch, Suzanne Fields Jones, Mythili Shastry, Denise Aysel Yardley, Howard A. Burris, David Robert Spigel et al. · 2021 · JCO Precision Oncology
A review of immune checkpoint blockade in breast cancer
Benedetta Pellegrino, Chiara Tommasi, Olga Elisabetta Cursio, Antonino Musolino, Edoardo Migliori, Pushpamali De Silva, Thilini Hemali Senevirathne, Marina Schena, Mario Scartozzi, Daniele Farci et al. · 2021 · Seminars in Oncology
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis
Alessandro Rizzo, Veronica Mollica, Sara Merler, Franco Morelli, Giulia Sorgentoni, Marco Oderda, Matteo Santoni, Francesco Massari · 2022 · Expert Opinion on Drug Metabolism & Toxicology
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhaï, Silvia Mihaela Ilie, Audrey Hennequin et al. · 2022 · Breast Cancer Research
Evaluating everolimus for the treatment of breast cancer
Camille Moreau-Bachelard, Marie Robert, Carole Gourmelon, Emmanuelle Bourbouloux, Anne Patsouris, Jean‐Sébastien Frenel, Mario Campone · 2023 · Expert Opinion on Pharmacotherapy
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
Emma Zattarin, Ida Taglialatela, Riccardo Lobefaro, Rita Leporati, Giovanni Fucà, Francesca Ligorio, Caterina Sposetti, Leonardo Provenzano, Jacopo Azzollini, Andrea Vingiani et al. · 2023 · Critical Reviews in Oncology/Hematology
ER-positive and BRCA2-mutated breast cancer: a literature review
Pu‐Chun Li, Yifan Zhu, Wen‐Ming Cao, Bei Li · 2024 · European journal of medical research
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
Charlotte S. Walmsley, Philip Jonsson, Michael L. Cheng, Sean Matthew McBride, Christopher Kaeser, Herbert Alberto Vargas, Vincent Paul Laudone, Barry S. Taylor, Rajya L. Kappagantula, Priscilla Baez et al. · 2024 · npj Precision Oncology
Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib
Jacob Mentzel, Laura S. Hildebrand, Lukas Kuhlmann, Rainer Fietkau, Luitpold Valentin Distel · 2024 · International Journal of Molecular Sciences
Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action
Nneoma James, Esther Owusu, Gildardo Rivera, Debasish Bandyopadhyay · 2024 · International Journal of Molecular Sciences
Advances in Personalized Oncology
Hiba Mechahougui, James Gutmans, Gina Colarusso, Roumaïssa Gouasmi, Alex Friedlaender · 2024 · Cancers
New Therapeutic Options for BRCA Mutant Patients
Anthony Ghanem, Susan M. Domchek · 2024 · Annual Review of Medicine
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response
Andge Valiakhmetova, Sergey Gorelyshev, Alexander N. Konovalov, Yu. Yu. Trunin, Alexander N. Savateev, David E. Kram, Eric Allan Severson, Amanda C. Hemmerich, Claire I. Edgerly, Daniel L. Duncan et al. · 2019 · The Oncologist
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations
Yolanda Jerez, Iván Márquez‐Rodas, Inmaculada Aparicio, Manuel Alva, Miguel Martín, Sara López‐Tarruella · 2019 · Drugs
Novel targeted therapies for metastatic breast cancer
Khalid Jazieh, Ruth Bell, Nayan Agarwal, Jame Abraham · 2020 · Annals of Translational Medicine
Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials
Mohamed A. Elmeliegy, Yanke Yu, Jennifer Keating Litton, Akos Gabor Czibere, Gary G. Wilson, Iulia Cristina Tudor, Jenny Zheng, Diane D. Wang · 2020 · The Journal of Clinical Pharmacology
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative
Neelima Vidula, Leif William Ellisen, Aditya Bardia · 2021 · Journal of the National Comprehensive Cancer Network
Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan
Hikmat Abdel‐Razeq, Lama Abujamous, Mahmoud Abunasser, Sara Edaily, Rayan Bater · 2021 · Scientific Reports
Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer
Jason Aboudi Mouabbi, Charles Kent Osborne, Rachel Schiff, Mothaffar Fahed Rimawi · 2021 · Breast Cancer Research and Treatment
Advances in the management of breast cancer brain metastases
Sarah LeNoir Sammons, Amanda E.D. Van Swearingen, Caroline D. Chung, Carey K. Anders · 2021 · Neuro-Oncology Advances
Establishment and Characterization of a Brca1−/−, p53−/− Mouse Mammary Tumor Cell Line
Lilla Hámori, Gyöngyi Kudlik, Kornélia Szebényi, Nóra Kucsma, Bálint Szeder, Ádám Póti, Ferenc Uher, György Várady, Dávid Szüts, József Tóvári et al. · 2020 · International Journal of Molecular Sciences
Single-cell sequencing unveils mitophagy-related prognostic model for triple-negative breast cancer
Peikai Ding, Shengbin Pei, Zheng Qu, Yazhe Yang, Qiang Liu, Xiangyi Kong, Zhongzhao Wang, Jing Wang, Yi Fang · 2024 · Frontiers in Immunology
DNA damage response inhibitors in cancer therapy: Mechanisms, clinical development, and combination strategies
Seon‐gyeong Lee, Jinwoo Kim, Euihwan Jeong, Kyungjae Myung · 2025 · DNA repair
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2
Nadine Tung, Mark E. Robson, Tianyu Li, Rita Nanda, Payal Deepak Shah, Katia E. Khoury, Gretchen Genevieve Kimmick, Cesar Augusto Santa-Maria, Adam Brufsky, Michelle K. DeMeo et al. · 2026 · Journal of Clinical Oncology
BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
Shan Li, Tao Li, Haiyun Dai, Xue Gong, Yuguo Zhuo, Hui Xiang, Yueyang Zhao, Qing Gao, Liang Deng · 2021 · Frontiers in Oncology
Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes
Elaine M. Walsh, Neha S. Mangini, John H. Fetting, Deborah Kay Armstrong, Isaac S. Chan, Roisín M. Connolly, Katie Fiallos, Jennifer Lehman, Raquel Nunes, Dana Petry et al. · 2021 · Clinical Breast Cancer
A phase I study of talazoparib ( BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors ( NCI9782 )
Ticiana A.B. Leal, Marina Nasrin Sharifi, Nancy Chan, Robert Wesolowski, Anita Ahmed Turk, Justine Y. Bruce, Ruth M O'Regan, Jens C. Eickhoff, Lisa Marie Barroilhet, Jyoti Dhar Malhotra et al. · 2022 · Cancer Medicine
DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives
Öykü Gönül Geyik, Giulia Anichini, Engı̇n Ulukaya, Fabio Marra, Chiara Raggi · 2022 · Cells
A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes
Tae-Kyung Robyn Yoo, Jun Kyu Kang, A-Won Lee, Byung Joo Chae · 2022 · Breast Cancer Research and Treatment
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra, Karim S. Fizazi, Johann Sebastian De Bono, Philippe Barthélémy, Tanya Barauskas Dorff, Adam Stirling, Jean‐Pascal Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez et al. · 2022 · The Oncologist
Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape
Jacopo Uliano, Eleonora Nicolò, Carla Corvaja, Beatrice Taurelli Salimbeni, Dario Trapani, Giuseppe Curigliano · 2022 · Expert Review of Clinical Pharmacology
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results
Fortunato Ciardiello, Yung‐Jue Bang, Andrès M.R. Cervantes, Mikhail Vladimirovich Dvorkin, Charles D. Lopez, Jean‐Philippe Metges, Antonio Sánchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis et al. · 2023 · Cancer Medicine
DNA repair pathways in breast cancer: from mechanisms to clinical applications
Muhammad Tufail · 2023 · Breast Cancer Research and Treatment
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments
Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca I. Moscetti et al. · 2023 · European Journal of Cancer
An autophagy-inducing stapled peptide induces mitochondria dysfunction and triggers autotic cell death in triple-negative breast cancer
Xiaozhe Zhang, Shan Gao, Na Li, Jingyi Chen, Changyang Ji, Xiaoxiao Li, Liwen Jiang, Terence K. Lee, Vincent W. Keng, Yanxiang Zhao · 2023 · Cell Death Discovery
Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
Eunice Yoojin Lee, Dae‐Won Lee, Kyung-Hun Lee, Seock‐Ah Im · 2023 · Cancer Research and Treatment
Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States
Anju Murayama, Deborah Catherine Marshall · 2023 · Gynecologic Oncology
Cancer genetic counselling for hereditary breast cancer in the era of precision oncology
Matilde Pensabene, Alessandra Calabrese, Claudia von Arx, R. Caputo, Michelino De Laurentiis · 2024 · Cancer Treatment Reviews
Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance
Dong Won Baek, Ji Young Park, Soo Jung Lee, Yee Soo Chae · 2020 · Journal of Yeungnam Medical Science
Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years
Anna Thulin, Elisabeth Werner Rönnerman, Chenyang Zhang, Shahin De Lara, Chaido Chamalidou, Arnd Schoenfeldt, Carola Andersson, Anikó Kovács, Fredrik Enlund, Barbro Kristina Linderholm · 2020 · The Breast
Current and emerging biologic therapies for triple negative breast cancer
Saba S. Shaikh, Leisha A. Emens · 2020 · Expert Opinion on Biological Therapy
Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer
Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo, Shunrong Ji · 2020 · Experimental Hematology and Oncology
American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer
Cheng Har Yip, Lisa A. Newman · 2021 · JAMA Surgery